화학 요법을 받는 환자에서 18F Florbetapir의 심장 흡수

실험적: AL 심장 아밀로이드 환자

등록된 환자는 심장 AL 아밀로이드증의 임상 진단(전형적인 심초음파 또는 MRI 소견, 332pg/mL 이상의 NT-ProBNP 수준, 경쇄 아밀로이드증의 심장 또는 심장외 조직학적 증거)이 있는 18세 초과의 환자이며 치료를 받을 계획입니다. 형질 세포 유도 화학 요법.

의약품: F18 플로베타피르(아미비드) 심장 PET/CT 영상

계획된 형질 세포 유도 화학 요법을 받는 심장 아밀로이드증(AL) 환자는 화학 요법을 시작하기 전과 치료 시작 6개월 후에 F-18 플로르베타피르(아미비드) 심장 PET/CT 영상을 받게 됩니다.

다른 이름들:

• 아미비드

Relative Change in Cardiac Uptake of 18F Florbetapir Prior to Chemotherapy and After Six Months of Chemotherapy.

Levels of 18F florbetapir cardiac uptake at onset of chemotherapy will be compared with levels after six months of chemotherapy on repeat imaging.

Six Minute Walk Test

Change in Distance covered on six minute walk test at onset of chemotherapy will be compared to distance covered after six months of chemotherapy Distance at onset vs six months will be correlated with changes in 18F florbetapir cardiac uptake on cardiac PET/CT imaging between 0 and 6 months. Overall change in distance walked during 6 minute walk prior to starting chemotherapy and after 12 months of chemotherapy will be compared to any changes in 18F florbetapir cardiac uptake on cardiac PET/CT imaging between 0 and 6 months.

Hematologic Response

correlation of hematologic response to treatment at 6 months and 18F florbetapir cardiac uptake changes between 0 and 6 months. Hematologic response after 12 months will also be compared to any changes in 18F florbetapir cardiac uptake between 0 and 6 months.

Cardiac Response

Cardiac response as defined by changes in NT proBNP (N Terminal proBNP) levels and cardiac Troponin T levels will be correlated with changes in 18F florbetapir cardiac uptake between 0 and 6 months. Changes in Cardiac troponin T and NT pro BNP levels after 12 months will also be correlated with changes in 18F florbetapir cardiac uptake between 0 and 6 months.

Patient Related Outcomes

Correlation of hematologic response to results of patient related outcomes survey completed at 0, 6, and 12 months.

Patient reported outcomes survey was developed using PROMIS short form v2.0-Physical Function 8b, PROMIS short form v1.0 Dyspnea Severity 10a, and PROMIS short form v1.0 Fatigue 8a. Measures used in the patient survey were obtained from the health measures website at www.healthmeasures.net/promis, which can be accessed for further information. Scale 1-5 with one being not at all and 5 being very likely.

Patient Related Outcomes

Correlation of cardiac response to results of patient related outcomes survey completed at 0, 6, and 12 months

Patient reported outcomes survey was developed using PROMIS short form v2.0-Physical Function 8b, PROMIS short form v1.0 Dyspnea Severity 10a, and PROMIS short form v1.0 Fatigue 8a. Measures used in the patient survey were obtained from the health measures website at www.healthmeasures.net/promis, which can be accessed for further information. Scale 1-5 with one being not at all and 5 being very likely.

Patient Related Outcomes

Correlation changes in 18F florbetapir cardiac uptake between 0 and 6 months to results of patient related outcomes survey completed at 0, 6, and 12 months

Patient reported outcomes survey was developed using PROMIS short form v2.0-Physical Function 8b, PROMIS short form v1.0 Dyspnea Severity 10a, and PROMIS short form v1.0 Fatigue 8a. Measures used in the patient survey were obtained from the health measures website at www.healthmeasures.net/promis, which can be accessed for further information. Scale 1-5 with one being not at all and 5 being very likely.